

## **Publications Jan Beyer-Westendorf:**

Khorsand N, Majeed A, Sarode R, **Beyer-Westendorf J**, Schulman S, Meijer K; Subcommittee on the Control of Anticoagulation. Assessment of effectiveness of major bleeding management: Proposed definitions for effective hemostasis: communication from the SSC of the ISTH. *J Thromb Haemost*. 2015 Sep 22. doi: 10.1111/jth.13148.

**Beyer-Westendorf J**, Ageno W. Small clots with large impact. *Blood*. 2015 Aug 20;126(8):926-7. doi: 10.1182/blood-2015-07-653394.

Lee AY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, Khorana AA; **CATCH Investigators**. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. *JAMA*. 2015 Aug 18;314(7):677-86. doi: 10.1001/jama.2015.9243.

van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, **Beyer-Westendorf J**, Boda Z, Carrier M, Chlumsky J, Decousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso M, Büller HR, Raskob GE. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. *Thromb Haemost*. 2015 Aug 13;114(6).

Pannach S, **Beyer-Westendorf J**. [New oral anticoagulants and endoscopy--what do you have to consider?]. *Dtsch Med Wochenschr*. 2015 Aug;140(16):1227-30. doi: 10.1055/s-0041-102666.

Ageno W, Riva N, Schulman S, **Beyer-Westendorf J**, Bang SM, Senzolo M, Grandone E, Pasca S, Di Minno MN, Duce R, Malato A, Santoro R, Poli D, Verhamme P, Martinelli I, Kamphuisen P, Oh D, D'Amico E, Becattini C, De Stefano V, Vidili G, Vaccarino A, Nardo B, Di Nisio M, Dentali F. Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. *JAMA Intern Med*. 2015 Sep 1;175(9):1474-80. doi: 10.1001/jamainternmed.2015.3184.

**Beyer-Westendorf J**, Gehrlich S, Stange T, Tittl L, Siegert G, Weiss N. Coagulation activation after discontinuation of VTE treatment with different oral anticoagulants and impact on 12-month clinical outcomes. *Thromb Res*. 2015 Aug;136(2):261-6. doi: 10.1016/j.thromres.2015.06.003.

Kepplinger J, Prakapenia A, Barlind K, Siegert G, Gehrlich S, Zerna C, **Beyer-Westendorf J**, Puetz V, Reichmann H, Siepmann T, Bodechtel U. Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol. *J Thromb Thrombolysis*. 2015 May 23.

Weitz JI, Bauersachs R, **Beyer-Westendorf J**, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Holberg G, Kakkar A, Lensing AW, Prins M, Haskell L, van Bellen B, Verhamme P, Wells PS, Prandoni P; EINSTEIN CHOICE Investigators. Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. *Thromb Haemost*. 2015 Aug 31;114(3):645-50. doi: 10.1160/TH15-02-0131.

Michalski F, Tittl L, Werth S, Hänsel U, Pannach S, Sahin K, Weiss N, **Beyer-Westendorf J**. Selection, management, and outcome of vitamin K antagonist-treated patients with atrial fibrillation not switched to novel oral anticoagulants. Results from the Dresden NOAC registry. *Thromb Haemost*. 2015 May 21;114(4).

Werth S, Breslin T, NiAinle F, **Beyer-Westendorf J**. Bleeding Risk, Management and Outcome in Patients Receiving Non-VKA Oral Anticoagulants (NOACs). *Am J Cardiovasc Drugs*. 2015 Aug;15(4):235-42. doi: 10.1007/s40256-015-0123-6.

**Beyer-Westendorf J**, Siegert G. Of men and meals. *J Thromb Haemost*. 2015 Jun;13(6):943-5. doi: 10.1111/jth.12973.

**Beyer-Westendorf J**, Ebertz F, Förster K, Gelbricht V, Michalski F, Köhler C, Werth S, Endig H, Pannach S, Tittl L, Sahin K, Daschkow K, Weiss N. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. *Thromb Haemost*. 2015 Mar 5;113(6).

Zolfaghari S, Harenberg J, Frölich L, Weiss C, Wehling M, Wild P, Prochaska J, **Beyer-Westendorf J**, Koscielny J, Lip GYH. Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference. *Semin Thromb Hemost* 2015;41:166–177

**Beyer-Westendorf J**, Förster K, Ebertz F, Gelbricht V, Schreier T, Göbelt M, Michalski F, Endig H, Sahin K, Tittl L, Weiss N. Drug persistence with rivaroxaban therapy in atrial fibrillation patients – results from the Dresden NOAC registry. *Europace*. 2015 Feb 17. pii: euu319

**Beyer-Westendorf J**. Bleeding complications under oral anticoagulation. *Dtsch Med Wochenschr*. 2015 Feb;140(3):214-5

**Beyer-Westendorf J**. Bleeding complications under oral anticoagulation. *Dtsch Med Wochenschr*. 2014 Dec;139(49):2491-3.

Prins MH, Lensing AWA, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, **Beyer-Westendorf J**, Pap AF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. *Lancet Hematology* 2014; [http://dx.doi.org/10.1016/S2352-3026\(14\)70018-3](http://dx.doi.org/10.1016/S2352-3026(14)70018-3)

Bauersachs RM, Lensing AWA, Prins MH, Kubitza D, Pap AF, Decousus H, **Beyer-Westendorf J**, Prandoni P. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. *Thrombosis J* 2014; *Thromb J*. 2014 Nov 24;12:25. doi: 10.1186/1477-9560-12-25. eCollection 2014

**Beyer-Westendorf J**, Marten S. Fallstricke bei der Thrombosetherapie. *Der Hausarzt* 2014; 17: 59-62.

**Beyer-Westendorf J**, Ageno W. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism. *Thromb Haemost.* 2015 Jan 27;113(2):231-46

**Beyer-Westendorf J**, Halbritter K. [Aggressive treatment of deep vein thrombosis - contra]. *Zentralbl Chir.* 2014 Oct;139(5):539-45

Werth S, Kamvissi V, Stange T, Kuhlisch E, Weiss N, **Beyer-Westendorf J**. Outpatient or inpatient treatment for acute pulmonary embolism: a retrospective cohort study of 439 consecutive patients. *J Thromb Thrombolysis.* 2014 Oct 11

Werth S, **Beyer-Westendorf J**. Apixaban. *Arzneimittel-Therapie-Kritik* 2014; 46:127-130

Kamphuisen PW, **Beyer-Westendorf J**. Bleeding complications during anticoagulant treatment in patients with cancer. *Thromb Res.* 2014 May;133 Suppl 2:S49-55

**Beyer-Westendorf J**, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, Köhler C, Werth S, Sahin K, Tittl L, Hänsel U, Weiss N. Rates, management and outcome of bleeding complications during rivaroxaban therapy in daily care: results from the Dresden NOAC registry. *Blood.* 2014 May 23. pii: blood-2014-03-563577.

Cohen AT, Spiro TE, Spyropoulos AC, Desanctis YH, Homering M, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Tapson VF, Burton P; **MAGELLAN Study Group**. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. *J Thromb Haemost.* 2014 Apr;12(4):479-87. doi: 10.1111/jth.12515.

Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, **Beyer-Westendorf J**, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. *N Engl J Med.* 2014 Apr 10;370(15):1402-11

Schindewolf M, Steindl J, **Beyer-Westendorf J**, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pöttsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Kropff S, Müller MM, Lindhoff-Last E. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT) - findings from the GerHIT multi-centre registry study. *Thromb Res.* 2014 Mar 18. pii: S0049-3848(14)00159-5. doi: 10.1016/j.thromres.2014.03.029

**Beyer-Westendorf J**, Gelbricht V, Förster K, Ebertz F, Röllig D, Schreier T, Tittl L, Thieme C, Hänsel U, Köhler C, Werth S, Kuhlisch E, Stange T, Röder I, Weiss N. Safety of switching from Vitamin-K antagonists to dabigatran or rivaroxaban in daily care - results from the Dresden NOAC registry. *Br J Clin Pharmacol.* 2014 Apr 2. doi: 10.1111/bcp.12391

Kleinjan A, Di Nisio M, **Beyer-Westendorf J**, Camporese G, Cosmi B, Ghirarduzzi A, Kamphuisen PW, Otten HM, Porreca E, Aggarwal A, Brodmann M, Guglielmi MD, Iotti M, Kaasjager K, Kamvissi V, Lerede T, Marschang P, Meijer K, Palareti G, Rickles FR, Righini

M, Rutjes AW, Tonello C, Verhamme P, Werth S, van Wissen S, Büller HR. Safety and Feasibility of a Diagnostic Algorithm Combining Clinical Probability, d-Dimer Testing, and Ultrasonography for Suspected Upper Extremity Deep Venous Thrombosis: A Prospective Management Study. *Ann Intern Med.* 2014 Apr 1;160(7):451-7. doi: 10.7326/M13-2056.

Werth S, **Beyer-Westendorf J.** Apixaban. *Internist. Praxis* 2014; 54:393-6.

**Beyer-Westendorf J,** Gelbricht V, Förster K, Ebertz F, Köhler C, Werth S, Kuhlisch E, Stange T, Thieme C, Daschkow K, Weiss N. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. *Eur Heart J.* 2014 Jan 6. [Epub ahead of print]

Agno W, Riva N, Schulman S, Bang SM, Sartori MT, Grandone E, **Beyer-Westendorf J,** Barillari G, Di Minno MN, Dentali F; on behalf of the IRSVT study group. Antithrombotic Treatment of Splanchnic Vein Thrombosis: Results of an International Registry. *Semin Thromb Hemost.* 2013 Dec 31. [Epub ahead of print]

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; **ENGAGE AF-TIMI 48 Investigators.** Edoxaban versus Warfarin in Patients with Atrial Fibrillation. *N Engl J Med.* 2013 Nov 28;369(22):2093-104

Kucher N, Boekstegers P, Müller O, Kupatt C, **Beyer-Westendorf J,** Heitzer T, Tebbe U, Horstkotte J, Müller R, Blessing E, Greif M, Lange P, Hoffmann RT, Werth S, Barmeyer A, Härtel D, Grünwald H, Empen K, Baumgartner I. Randomized Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism. *Circulation.* 2014 Jan 28;129(4):479-86

**Beyer-Westendorf J,** Gehrlich S. Pharmacokinetics of rivaroxaban in adolescents. *Hamostaseologie.* 2013 Oct 24;34(1). [Epub ahead of print]

**Beyer-Westendorf J,** Pannach S. Increase of gastrointestinal bleeding with new oral anticoagulants: problems of a meta-analysis. *Gastroenterology.* 2013 Nov;145(5):1162-3. doi: 10.1053/j.gastro.2013.09.041.

Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS. **The EINSTEIN investigators.** Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. *Thromb J.* 2013 Sep 20;11(1):21.

**The Hokusai-VTE Investigators.** Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. *N Engl J Med.* 2013 Aug 31. [Epub ahead of print]

Pannach S, Babatz J, **Beyer-Westendorf J.** Successful treatment of acute portal vein thrombosis with rivaroxaban. *Thromb Haemost.* 2013 Jul 11;110(4).

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; the **AMPLIFY Investigators.** Oral Apixaban for the

Treatment of Acute Venous Thromboembolism. *N Engl J Med*. 2013 Jul 1. [Epub ahead of print]

Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M. the **Hokusai-VTE investigators**. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. *J Thromb Haemost*. 2013 Jul;11(7):1287-94. doi: 10.1111/jth.12230.

Lee AY, Bauersachs R, Janas MS, Jarner MF, Kamphuisen PW, Meyer G, Khorana AA on behalf of the **CATCH Investigators**. CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients. *BMC Cancer*. 2013 Jun 13;13(1):284.

**Beyer-Westendorf J**, Weiss N. TIA: vitamin K antagonists versus antiplatelet drugs. *Dtsch Med Wochenschr*. 2013 Apr;138(17):876-877

Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, Kvanme AM, Friedman J, Mismetti P, Goldhaber SZ; **RE-MEDY Trial Investigators; RE-SONATE Trial Investigators**. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. *N Engl J Med*. 2013 Feb 21;368(8):709-18.

Mahlmann A, Gehrisch S, **Beyer-Westendorf J**. Pharmacokinetics of rivaroxaban after bariatric surgery: a case report. *J Thromb Thrombolysis*. 2013 Feb 17.

Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Spyropoulos AC, Tapson V; **MAGELLAN Investigators**. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. *N Engl J Med*. 2013 Feb 7;368(6):513-23.

**Beyer-Westendorf J**, Bogorad V, Tautenhahn I, Marten S, Schellong S. Predictors of deep venous thrombosis in patients admitted to rehabilitation clinics after major orthopaedic surgery. *Vasa*. 2013 Jan;42(1):40-9.

Halbritter K, **Beyer-Westendorf J**, Nowotny J, Pannach S, Kuhlisch E, Schellong SM. Hospitalization for Vitamin-K-Antagonist-related bleeding – treatment patterns and outcome. *J Thromb Haemost*. 2013 Apr;11(4):651-9. doi: 10.1111/jth.12148.

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; the **AMPLIFY-EXT Investigators**. Apixaban for Extended Treatment of Venous Thromboembolism. *N Engl J Med*. 2012 Dec 8. [Epub ahead of print]

**Beyer-Westendorf J**, Lützner J, Donath L, Tittl L, Knoth H, Radke OC, Kuhlisch E, Stange T, Hartmann A, Günther KP, Weiss N, Werth S. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery - Findings from the ORTHO-TEP registry. *Thromb Haemost* 2013; doi:10.1160/TH12-07-0510

Köhler C, Halbritter K, Stroszczyński C, Mahlmann A, **Beyer-Westendorf J**, Weiss N. Determinants of intermediate term clinical outcome after endovascular below-knee interventions. *Vasa*. 2012; 41:440-50

Koscielny J, **Beyer-Westendorf J**, von Heymann C, Braun J, Klamroth R, Lindhoff-Last E, Tiede A, Spannagl M. Blutungsrisiko und Blutungsnotfälle unter Rivaroxaban - Periinterventionelles Hämostasemanagement. *Hämostaseologie* 2012; 32: 287-293

**Beyer-Westendorf J**, Lützner J, Donath L, Radke OC, Kuhlisch E, Hartmann A, Weiss N, Werth S. Efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopaedic surgery - findings from the ortho-tep registry. *J Thromb Haemost.* 2012 Aug 6. doi: 10.1111/j.1538-7836.2012.04877.x.

Donath L, Lützner J, Werth S, Kuhlisch E, Hartmann A, Günther KP, Weiss N, **Beyer-Westendorf J**. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low-molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry. *Br J Clin Pharmacol.* 2012 Apr 20. doi: 10.1111/j.1365-2125.2012.04302.x.

**EINSTEIN-PE Investigators**, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med.* 2012; 366(14):1287-97.

Werth S, Halbritter K, **Beyer-Westendorf J**. Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery. *Ther Clin Risk Manag.* 2012;8:139-47.

Donath L, Lützner J, Werth S, Kuhlisch E, Hartmann A, Günther KP, Weiss N, **Beyer-Westendorf J**. Efficacy and safety of venous thromboembolism prophylaxis with fondaparinux or low-molecular weight heparin in a large cohort of consecutive patients undergoing major orthopaedic surgery - findings from the ORTHO-TEP registry. *Br J Clin Pharmacol.* 2012 Apr 20. doi: 10.1111/j.1365-2125.2012.04302.x.

**EINSTEIN-PE Investigators**, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med.* 2012;366(14):1287-97.

Werth, S., Halbritter, K. **Beyer-Westendorf, J.** Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopaedic surgery. *Therapeutics and Clinical Risk Management* 2012;8; 139–147.

**The Steering Committee, on behalf of the PEITHO Investigators.** Single-Bolus Tenecteplase Plus Heparin Compared With Heparin Alone for Normotensive Patients With Acute Pulmonary Embolism, Who Have Evidence of Right Ventricular Dysfunction and Myocardial Injury: Rationale and Design of the Pulmonary Embolism Thrombolysis (PEITHO) Trial. *Am Heart J.* 2012 Jan;163(1):33-38.e1.

Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM, Weitz JI; **ADOPT Trial Investigators.** *N Engl J Med.* 2011 Dec 8;365(23):2167-77. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

**Beyer-Westendorf J**, Büller H. External and Internal Validity of Open Label or Double Blind Trials in Oral Anticoagulation - Better, Worse or Just Different??? *J Thromb Haemost.* 2011;9(11):2153-8

**Beyer-Westendorf J**, Werth S. Neue Optionen in der Antikoagulation bei therapierefraktärem Trousseau-Syndrom. *Phlebologie.* 2011; 40: 211-215.

**Beyer-Westendorf J**, Werth S, Folprecht G, Weiss N. Trousseau's syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux. *Br J Clin Pharmacol.* 2011;72(4):715-6

Werth S, Rodionov RN, Hinterseher I, **Beyer-Westendorf J**, Stroszczyński C, Weiss N, Bergert H. Rupture prone aneurysm of the inferior mesenteric artery complicated by mid aortic syndrome with occluded celiac and superior mesenteric arteries. *Vasa.* 2011 Jan;40(1):73-7

**Beyer-Westendorf J**, Halbritter K, Platzbecker H, Damme U, Neugebauer B, Kuhlisch E, Schellong S. Central adjudication of venous ultrasound in VTE screening trials: reasons for failure. *J Thromb Haemost.* 2011 Mar;9(3):457-63

**EINSTEIN Investigators**, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med.* 2010 Dec 23;363(26):2499-510.

Braun S, **Beyer-Westendorf J**, Platzek I, Höffken G, Halank M. Acute pulmonary embolism. *Dtsch Med Wochenschr.* 2010;135:1803-1814.

Schwarz T, Buschmann L, **Beyer J**, Halbritter K, Rastan A, Schellong S. Therapy of isolated calf muscle vein thrombosis. A randomized, controlled study. *J Vasc Surg.* 2010 Nov;52(5):1246-50

**Beyer-Westendorf J**, Werth S, Halbritter K, Weiss N. Cancer in males and risk of venous thromboembolism. *Thromb Res.* 2010 Apr;125 Suppl 2: S155-9

Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; **RE-COVER Study Group**. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. *N Engl J Med.* 2009;361:2342-52.

**Beyer-Westendorf J**, Seitz W, Jabs N, Bramlage P, Kuhlisch E, Julius U, Bornstein SR, Schellong SM. Nitric oxide and endothelin after lipid apheresis – a pilot study. *Atherosclerosis* 2009; Supplements 10: 71-73.

Gibson NS, Schellong SM, El Kheir DY, **Beyer-Westendorf J**, Gallus AS, Mc Rae S, Schutgens RE, Piovella F, Gerdes VE, Buller HR. Safety and sensitivity of two ultrasound strategies in patients with clinically suspected deep venous thrombosis; a prospective management study. *J Thromb Haemost.* 2009 Oct 8. [Epub ahead of print]

**Beyer-Westendorf J.** Safety of venous ultrasound in suspected DVT--still a matter of concern? *Thromb Haemost.* 2009 Jul;102(1):5-6.

**Beyer J,** Wessela S, Hakenberg OW, Kuhlisch E, Halbritter K, Froehner M, Wirth MP, Schellong SM. Incidence, risk profile and morphological pattern of venous thromboembolism after prostate cancer surgery. *J Thromb Haemost.* 2009; 7: 597-604.

**Beyer J,** Halbritter K, Weise M, Schellong S. Influence of antithrombin and argatroban on disseminated intravascular coagulation parameters in a patient with septic shock. *Thromb Res.* 2009; 124: 383-6.

Braun S., **Beyer J.,** Höffken G., Halank, M. Akute Lungenembolie. *Atemw.-Lungenkrkh.* 2009; 35: 388-394.

**Beyer J,** Halank M, Ewert, R, Kolditz M, Rubens C, Opitz C, Schellong S, Hoeffken G. L-arginine plasma levels and severity of idiopathic pulmonary arterial hypertension. *Vasa* 2008; 37: 61-67.

**Beyer J,** Schellong S. Fibrinolytic therapy. *Hamostaseologie,* 2008; 28:428-37.

Hochauf S, **Beyer J.** Prophylaxis of venous thromboembolism. *Hamostaseologie,* 2008; 28: 217-24.

Stroszczyński C, **Beyer J,** Bergert H. Vascular recanalization techniques: renal artery stenoses. *Radiologe.* 2008 May 16.

**Beyer J,** Schellong S. Anticoagulant therapy in venous thromboembolism. *Herz.* 2008; 33:52-8.

Schellong SM, **Beyer J,** Kakkar AK, Halbritter K, Eriksson BI, Turpie AG, Misselwitz F, Kälebo P. Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study. *J Thromb Haemost.* 2007; 5: 1431-7.

**Beyer J,** Sternitzky R, Hochauf S, Halbritter K, Schellong S. Diagnostik der venösen Thrombembolie - Ist der Goldstandard 'Phlebografie' bald überholt?. *Der Klinikarzt* 2007, 08:

Hochauf S, **Beyer J,** Sternitzky R, Schellong SM.  
Die Therapie der venösen Thromboembolie - Von der Akutbehandlung bis zur  
Erhaltungstherapie. *Der Klinikarzt* 2007; 08

**Beyer J,** Halbritter K, Weise M, Leonhard J, Schellong S. Heparin-induced thrombocytopenia II-induced critical limb ischaemia treated with urokinase and argatroban. *Thromb Haemost.* 2007; 98(2):470-2.

**Beyer J,** Schellong S. Bilateral plantar tendinitis during levofloxacin therapy. *Br J Clin Pharmacol.* 2006; 61(5):609.

Halbritter KM, Wawer A, **Beyer J,** Oettler W, Schellong SM.  
Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective 1  
year registry of 311 episodes. *J Thromb Haemost.* 2005; 3: 2823-5.

**Beyer J**, Schellong S. Fibrinolytic therapy  
Hamostaseologie. 2005, 25:345-55.

**Beyer J**, Schellong S. Deep vein thrombosis: Current diagnostic strategy.  
Eur J Intern Med. 2005 Aug;16(4):238-46.

Schellong SM; **Beyer J**.  
Duplexsonografie der Gefäße. Eine Übersicht für den anfordernden Arzt. Internist. Praxis  
2005; 45:463-93.

**Beyer J**, Schellong S. Deep Venous Thrombosis and Pulmonary Embolism. Prophylaxis and  
Therapy. Herz. 2005; 30: 204-211.

Schwarz T, Siegert G, Oettler W, Halbritter K, **Beyer J**, Frommhold R, Gehrisch S, Lenz F,  
Kuhlich E, Schroeder HE, Schellong SM. Venous thrombosis after long-haul flights. Arch  
Intern Med. 2003 Dec 8-22; 163(22): 2759-64.

Schellong SM, Schwarz T, Halbritter K, **Beyer J**, Siegert G, Oettler W, Schmidt B, Schroeder  
HE. Complete compression ultrasonography of the leg veins as a single test for the diagnosis  
of deep vein thrombosis. Thromb Haemost. 2003; 89: 228-34.

Schwarz T, Langenberg K, Oettler W, Halbritter K, **Beyer J**, Siegert G, Gehrisch S,  
Schroeder HE, Schellong SM. Deep vein and isolated calf muscle vein thrombosis following  
long-haul flights: pilot study. Blood Coagul Fibrinolysis. 2002; 13: 755-7.

Schwarz T, Schmidt B, **Beyer J**, Schröder HE, Schellong SM. Eligibility for home treatment  
of deep vein thrombosis: a prospective study in 202 consecutive patients. J Vasc Surg. 2001;  
34: 1065-70.

Schwarz T, Schmidt B, **Beyer J**, Schellong SM.  
Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin.  
Blood Coagul Fibrinolysis. 2001; 12: 597-9.

Schwarz T, Schmidt B, Hühlein U, **Beyer J**, Schröder HE, Schellong SM.  
Eligibility for home treatment of deep vein thrombosis: prospective study. BMJ. 2001 May  
19;322(7296):1212-3.

Garlichs CD, **Beyer J**, Zhang H, Schmeisser A, Plötze K, Mügge A, Schellong S, Daniel WG.  
Decreased plasma concentrations of L-hydroxy-arginine as a marker of reduced NO formation  
in patients with combined cardiovascular risk factors.  
J Lab Clin Med. 2000; 135: 419-25.

## **Book chapters**

**Beyer-Westendorf J**, Weiss N. „Lokale Komplikationen“ in: Komplikationen kompakt: Orthopädie und Unfallchirurgie. Wirth, Mutschler, Neu (edt.). Thieme 2015

**Beyer-Westendorf J**, Konstantinides S., Kucher N. „akute Lungenembolie“ in: Rationelle Diagnostik in der Inneren Medizin. Mayet, Mertens, Meyer, Müller, Pfeifer, Pletz, Schellinger, Weiss, Wendtner (edt.), Elsevier, Urban & Fischer, 2014

Bauersachs R, Hach-Wunderle V, Ludwig M, Stiegler H, **Beyer-Westendorf J**. „Venenthrombose“ in: Rationelle Diagnostik in der Inneren Medizin. Mayet, Mertens, Müller, Pfeifer, Pletz, Schellinger, Weiss (edt.), Elsevier, Urban & Fischer, 2012

**Beyer-Westendorf J**. „Neue Antikoagulanzen – was müssen Hämatologen und Onkologen wissen?“ in: Colloquium Onkologie 9; Dresdner Symposium Hämatologie und Onkologie 2009. Ehniger, Freund, Overkamp (edt.). Lukon 2010, 158-170.

**Beyer J**, Weiss N. „Lokale Komplikationen“ in: Komplikationen in Orthopädie und Unfallchirurgie. Wirth, Mutschler, Bischoff, Püschmann (edt.). Thieme 2009

**Beyer J**, Schellong S. “The search for Deep Vein Thrombosis“ in: Management of Acute Pulmonary Embolism. Konstantinides, S (edt.), Humana Press 2007, 43-55.